Business
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for
About this update from Revolution Medicines, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the RASolute 304 trial. RASolute 304 is a global, open-label, Phase 3 clinical trial evaluating the safety and efficacy of daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with resectable pancreatic ductal adenocarcinoma (PDAC) who have received surgery and chemotherapy. RASolute 304 is anticipated to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations who have undergone resection and completed perioperative chemotherapy. The trial will assess whether daraxonrasib can improve disease-free survival compared to observation. The primary endpoint in RASolute 304 is disease-free survival, and secondary endpoints include overall survival, safety, and tolerability. “We are pleased to begin enrolling patients into RASolute 304, which expands the clinical evaluation of daraxonrasib into another important treatment setting for patients with RAS mutant pancreatic cancer,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “This trial enables us to investigate daraxonrasib even earlier in the treatment paradigm, which could potentially improve the rate of long-term disease-free survival in patients with resectable pancreatic cancer.” Daraxonrasib is currently being evaluated in four global Phase 3 clinical trials, including three trials in PDAC and a trial in locally advanced or metastatic RAS mutant non-small cell lung cancer. About Pancreatic Cancer and Pancreatic Ductal AdenocarcinomaPancreatic cancer is one of the most lethal malignancies, characterized by its typically late-stage diagnosis, resistance to standard chemotherapy, and high mortality rate. In the U.S., recent estimates indicate that approximately 60,000 people will be diagnosed annually with pancreatic cancer, and about 50,000 people will die from this aggressive disease.1 Due to the lack of early symptoms and detection methods, approximately 80% of patients are diagnosed with PDAC at an advanced or metastatic stage. It is the most commonly RAS-addicted of all major cancers, and more than 90% of patients have tumors that harbor RAS mutations.2 Metastatic PDAC remains one...